Amarin_Logo_JPEG.jpg
Amarin Announces CEO Succession Plan
April 12, 2021 16:30 ET | Amarin Corporation plc
John Thero to Retire as President and CEO on August 1, 2021 Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor DUBLIN, Ireland and BRIDGEWATER, N.J., April ...
Amarin_Logo_JPEG.jpg
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
April 06, 2021 06:05 ET | Amarin Corporation plc
Reimbursement dossiers for first 10 countries to be filed in coming months 150 people hired and on-track to be deployed by mid-Q2 2021 supplemented by digital outreach and medical education programs...
Amarin_Logo_JPEG.jpg
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
March 30, 2021 06:24 ET | Amarin Corporation plc
Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and other risk characteristics as...
Amarin_Logo_JPEG.jpg
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is Rapidly Becoming a New Standard of Care
March 29, 2021 07:00 ET | Amarin Corporation plc
Recent recommendations or guidances, from Canada and Egypt, expand the global recognition of this important therapy and its demonstrated favorable outcomes study results DUBLIN, Ireland and...
Amarin_Logo_JPEG.jpg
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021
March 17, 2021 11:30 ET | Amarin Corporation plc
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%,...
Amarin_Logo_JPEG.jpg
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
February 25, 2021 05:55 ET | Amarin Corporation plc
Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received Positive CHMP Opinion for VAZKEPA® in Europe and Continue to Advance...
Amarin_Logo_JPEG.jpg
Amarin to Present at Two Upcoming Investor Conferences
February 18, 2021 06:05 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is...
Amarin_Logo_JPEG.jpg
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
February 17, 2021 08:05 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior...
Amarin_Logo_JPEG.jpg
Amarin Provides Update on VASCEPA® (Icosapent Ethyl) Regulatory Review Processes in Mainland China and Hong Kong
February 09, 2021 07:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that its corporate partner in China, Edding, has progressed VASCEPA®...
Amarin_Logo_JPEG.jpg
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
January 29, 2021 12:52 ET | Amarin Corporation plc
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study European Commission decision on the Marketing Authorisation...